{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:56:35Z","timestamp":1784735795813,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670611"],"award-info":[{"award-number":["81670611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11255-019-02093-6","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T09:35:21Z","timestamp":1549877721000},"page":"671-676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex"],"prefix":"10.1007","volume":"51","author":[{"given":"Wenda","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"key":"2093_CR1","first-page":"CD011272","volume":"7","author":"TH Sasongko","year":"2016","unstructured":"Sasongko TH, Ismail NF, Zabidi-Hussin Z (2016) Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev 7:CD011272","journal-title":"Cochrane Database Syst Rev"},{"key":"2093_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","volume":"615","author":"JP Osborne","year":"1991","unstructured":"Osborne JP, Fryer A, Webb D (1991) Epidemiology of tuberous sclerosis. Ann NY Acad Sci 615:125\u2013127","journal-title":"Ann NY Acad Sci"},{"issue":"4","key":"2093_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group (2013) Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49(4):243\u2013254","journal-title":"Pediatr Neurol"},{"issue":"2","key":"2093_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1053\/j.ajkd.2011.10.013","volume":"59","author":"K Budde","year":"2012","unstructured":"Budde K, Gaedeke J (2012) Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. Am J Kidney Dis 59(2):276\u2013283","journal-title":"Am J Kidney Dis"},{"issue":"9869","key":"2093_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869):817\u2013824","journal-title":"Lancet"},{"issue":"2","key":"2093_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358(2):140\u2013151","journal-title":"N Engl J Med"},{"issue":"17","key":"2093_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595\u20131606","journal-title":"N Engl J Med"},{"issue":"9","key":"2093_CR8","doi-asserted-by":"publisher","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora SL, Franz DN, Ashwal S et al. (2011) Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS ONE 6(9):e23379","journal-title":"PLoS ONE"},{"issue":"12","key":"2093_CR9","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies DM, de Vries PJ, Johnson SR et al (2011) Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 17(12):4071\u20134081","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2093_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","volume":"12","author":"MK Koenig","year":"2012","unstructured":"Koenig MK, Hebert AA, Roberson J et al (2012) Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R&D 12(3):121\u2013126","journal-title":"Drugs R&D"},{"key":"2093_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1750-1172-7-87","volume":"7","author":"C Cabrera-L\u00f3pez","year":"2012","unstructured":"Cabrera-L\u00f3pez C, Mart\u00ed T (2012) Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J Rare Dis 7:87","journal-title":"Orphanet J Rare Dis"},{"issue":"5327","key":"2093_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M Slegtenhorst van","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C et al (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277(5327):805\u2013808","journal-title":"Science"},{"issue":"7","key":"2093_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","unstructured":"European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75(7):1305\u20131315","journal-title":"Cell"},{"issue":"1","key":"2093_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora SL, Jozwiak S, Franz DN et al (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68(1):64\u201380","journal-title":"Am J Hum Genet"},{"key":"2093_CR15","doi-asserted-by":"publisher","first-page":"170.e1","DOI":"10.1016\/j.urology.2016.10.056","volume":"101","author":"Y Cai","year":"2017","unstructured":"Cai Y, Li H, Zhang Y (2017) Assessment if tuberous sclerosis complex associated with renal lesions by targeted next-generation sequencing in mainland China. Urology 101:170.e1\u2013170.e7","journal-title":"Urology"},{"issue":"11","key":"2093_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1101\/gad.901101","volume":"15","author":"X Gao","year":"2001","unstructured":"Gao X, Pan D (2001) TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15(11):1383\u20131392","journal-title":"Genes Dev"},{"issue":"1","key":"2093_CR17","first-page":"21","volume":"59","author":"J Koz\u0142owska","year":"2008","unstructured":"Koz\u0142owska J, Oko\u0144 K (2008) Renal tumors in postmortem material. Pol J Pathol 59(1):21\u201325","journal-title":"Pol J Pathol"},{"issue":"1","key":"2093_CR18","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1159\/000320891","volume":"118","author":"BP Dixon","year":"2011","unstructured":"Dixon BP, Hulbert JC, Bissler JJ (2011) Tuberous sclerosis complex renal disease. Nephron Exp Nephrol 118(1):e15\u2013e20","journal-title":"Nephron Exp Nephrol"},{"issue":"2","key":"2093_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/PAS.0b013e31817ed7a6","volume":"33","author":"H Aydin","year":"2009","unstructured":"Aydin H, Magi-Galluzzi C, Lane BR et al (2009) Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 33(2):289\u2013297","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2093_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40265-016-0552-9","volume":"76","author":"P Curatolo","year":"2016","unstructured":"Curatolo P, Bj\u00f8rnvold M, Dill PE et al (2016) The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. Drugs 76(5):551\u2013565","journal-title":"Drugs"},{"issue":"4","key":"2093_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group (2013) Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49(4):255\u2013265","journal-title":"Pediatr Neurol"},{"issue":"12","key":"2093_CR22","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","volume":"17","author":"JP MacKeigan","year":"2015","unstructured":"MacKeigan JP, Krueger DA (2015) Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol 17(12):1550\u20131559","journal-title":"Neuro Oncol"},{"issue":"5","key":"2093_CR23","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/bcp.12834","volume":"81","author":"K Budde","year":"2016","unstructured":"Budde K, Zonnenberg BA, Frost M et al (2016) Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br J Clin Pharmacol 81(5):958\u2013970","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2093_CR24","doi-asserted-by":"publisher","first-page":"e56199","DOI":"10.1371\/journal.pone.0056199","volume":"8","author":"IA Malinowska","year":"2013","unstructured":"Malinowska IA, Lee N, Kumar V et al (2013) Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis. PLoS ONE 8(2):e56199","journal-title":"PLoS ONE"},{"issue":"2","key":"2093_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","volume":"4","author":"JB Brugarolas","year":"2003","unstructured":"Brugarolas JB, Vazquez F, Reddy A et al (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4(2):147\u2013158","journal-title":"Cancer Cell"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02093-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T19:11:32Z","timestamp":1581361892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02093-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02093-6","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]},"assertion":[{"value":"29 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of Peking Union Medical College Hospital (Beijing, China).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent for publication was obtained from all the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}